CDK9 Opportunity SELLAS is advancing SLS009, a potent CDK9 inhibitor, with Phase 2 data in AML and expansion into Europe through IMPACT-AML partnership. BD opportunities exist in hematologic malignancies and potential combos with standard therapies, offering cross-border licensing and co-development scenarios.

GPS WT1 Target Galinpepimut-S (GPS) targets WT1 and is licensed from Memorial Sloan Kettering, presenting a niche opportunity to collaborate on biomarker-driven trials across multiple tumor types. Potential for strategic partnerships or licensing to accelerate broader indicated uses and companion diagnostics.

Pipeline Synergy Distinct platforms GPS (WT1-targeted) and GFH009 (CDK9 inhibitor) provide portfolio diversification. Opportunities exist to bundle trials, co-market, or co-develop combination regimens, appealing to oncology networks seeking multi-mechanism approaches.

European Expansion Recent move to expand SLS009 clinical program into Europe via IMPACT-AML creates regional access points for trials, regulatory engagement, and partner recruitment. Business development can target European CROs, hospitals, and pharma collaborators for faster patient enrollment.

Clinical Momentum Active conference presence and ongoing release of positive Phase 2 data (ASH 2025, AACR 2026) indicate a company with growing clinical momentum. Leverage this trajectory to approach strategic investors, potential co-development partners, and larger pharma interested in late-stage oncology assets.